Title:Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders
VOLUME: 22 ISSUE: 23
Author(s):Xuan Thi-Anh Nguyen and Ly Le
Affiliation:School of Biotechnology, International University, Quarter 6, Linh Trung Ward, Thu Duc District, Ho Chi Minh City, Vietnam.
Keywords:Therapeutics, metabolic disorders, neurodegenerative diseases, common pathways.
Abstract:Background: Metabolic syndromes such as insulin resistance, type 2 diabetes and obesity share common
pathogenic pathways with some age-related neurodegenerative disorders. Impaired insulin signaling, inflammation,
mitochondrial dysfunction and ER stress can be both causatives and consequences in both groups of the
diseases. Patients with chronic metabolic disorders therefore have potential risks to develop neurological diseases
in late-age phase and vice versa those who with neurodegenerative diseases also have impairments in metabolic
signaling. Method: In this review, we summarize about the interrelation between pathogenic pathways, common
drug targets as well as known and developing therapeutics for these “modern” diseases. Results: There are conventional
medicines for insulin resistance associated metabolic disorders such as insulin analogues, insulin sensitizers and ER stress releasers
which have been suggested in the treatments of some neurodegenerative diseases. Some used or tested therapeutics such as bromocriptine,
memantine and -2A adrenergic antagonists for Parkinson’s and Alzheimer’s diseases, vice versa, were promisingly shown
as alternative or complementary drugs for metabolic syndromes. Conclusion: Therefore, it is important and possible to consider contemporary
control and intervention for both diseases.
